SC or IMPrevention of hepatitis B in the newborn of a HBV carrier-mother 200 IU w/in 12 hr after birth, may be repeated until seroconversion following vaccination. No measurable hepatitis B Ab titer & for continuous prevention 8 IU/kg every 2 mth.
Not to be administered into a blood vessel. Potential for developing IgA Ab & anaphylactic reactions after administration of blood components containing IgA in individuals who are IgA deficient. May reduce BP w/ anaphylactic reactions in patients who have tolerated previous treatment w/ human Ig. Regularly monitor Ab levels in newborn. Record name & product batch number upon administration. Carefully observe newborn shortly after inj. Discontinue immediately if allergic or anaphylactic reaction is suspected. Change in electrolyte conc or pH may result in precipitation or denaturisation of proteins when added w/ other prep.
May interfere w/ the development of an immune response to live attenuated virus vaccines eg, rubella, mumps, measles & varicella for a period of 3 mth.
Sign Out
